Using a CRISPR-based depletion technology and NGS overcomes limitations by targeting and removing abundant host and microbial rRNA sequences, making NGS suitable for pandemic preparedness.
Read More
Cue Health has received De Novo authorization from the FDA for its Cue COVID-19 Molecular Test, designed for both home and point-of-care use.
Read More
Delay in sepsis diagnosis increases the risk of dying by 8% every hour; and can lead to the unnecessary use of strong antibiotic therapies.
Read More
With the acquisition, Avacta gains Coris’ product portfolio including diagnostic tests for respiratory, gastro-enteric, and blood-borne pathogens and for the detection of antibiotic resistance markers.
Read More
This Class I recall is for certain COVID-19 at-home test kits containing liquid solution that may be contaminated with bacteria.
Read More